Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [(111)In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

BACKGROUND: (111)In[In]-BnDTPA-trastuzumab-NLS is a radiopharmaceutical with theranostic applications for imaging and Meitner-Auger electron (MAE) radioimmunotherapy (RIT) of HER2-positive breast cancer (BC). Nuclear localization sequence (NLS) peptides route the radiopharmaceutical to the nucleus o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Conrad, Prozzo, Vanessa, Aghevlian, Sadaf, Reilly, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772372/
https://www.ncbi.nlm.nih.gov/pubmed/36542157
http://dx.doi.org/10.1186/s41181-022-00186-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772372/
https://www.ncbi.nlm.nih.gov/pubmed/36542157
http://dx.doi.org/10.1186/s41181-022-00186-9

Ejemplares similares